Blog
Content about digital package inserts, regulation and pharmaceutical technology
RDC 885/2024: What Changes, Who Is Affected, and How to Comply in Practice
Detailed analysis of ANVISA's regulation on electronic package inserts: technical requirements, deadlines, penalties, and the real impact for pharmaceutical companies of all sizes.
Read more →Digital vs. Printed Package Inserts: The Numbers the Industry Needs to Know
Concrete data on costs, environmental impact, patient adherence, and legal risks comparing printed and digital package inserts.
Read more →RDC 885 Compliance Checklist: Month-by-Month Timeline Until December 2026
Detailed action plan with timeline, responsibilities, milestones, and common pitfalls to ensure compliance before ANVISA's final deadline.
Read more →Accessibility in Digital Package Inserts: What WCAG 2.1 AA Means in Practice
Technical guide on implementing real accessibility in digital insert portals, with common mistakes and how to test correctly.
Read more →Digital Inserts and ESG: How Regulatory Compliance Became a Competitive Advantage
Digitizing package inserts generates concrete, measurable ESG metrics. Learn how to transform a regulatory obligation into a differentiator for investors and consumers.
Read more →How Artificial Intelligence Is Transforming Patient Safety
AI-powered drug interaction checkers, language simplification, and specialized chatbots: the future of digital package inserts has already begun.
Read more →